| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | Pechala's Reports | Lubomir Pechala | ACORDA THERAPEUTICS INC (ACOR=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 29-Nov-2009 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (ACOR). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (ACOR). | 5 |
$18 |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Acorda Therapeutics has a current Overall Rating of F (Lowest Rating). | 7 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Acorda Therapeutics, Inc. | 40 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| Acorda Therapeutics | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ACORDA THERAPTUTICS INC (ACOR=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ACORDA THERAPTUTICS INC (ACOR=US) 2-weeks forecast | 1 |
$10 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACOR , AFFY , ANDS , BSTC , OMPI , TELK -- DRUGS | 3 |
$4 |
1.48% Nasdaq 0.00%
Research Reports
